Investigating the effect of some fluoroquinolones on C-reactive protein levels and ACh-Induced blood pressure reduction deviations after aging of diabetes in STZ-Induced diabetic wistar rats.

The treatment of infections in diabetic patients by fluoroquinolone antibiotics is associated with a reduced risk of coronary artery disease, and may improve endothelium-derived hyperpolarizing factor (EDHF) efficacy. The inflammatory marker C-reactive protein (CRP) is an important predictor of cardiovascular events, and vascular endothelium dysfunction, which makes this marker a target for drug-based treatment. This study aims to investigate the relation between the treatment by fluoroquinolones with CRP plasma levels, as well as acetylecholine (ACh)-induced small conductance calcium-activated potassium channels (SK)-dependent blood pressure (BP) reduction deviations in wistar rats after inducing a type 2-like diabetes with aging state after four months of streptozotocin (STZ) injection. Experimental animals were divided into four groups, group 1: diabetic animals were treated with moxifloxacin (n = 15), group 2: diabetic animals were treated with levofloxacin (n = 15), group 3: diabetic control animals (n = 15), and group 4: non-diabetic control animals (n = 6). The levels of plasma CRP, as well as ACh-induced SK-dependent BP reduction deviations were compared four months after the development of diabetes, after that; two groups were treated with fluoroquinolones, four months after the treatment; CRP-plasma levels, as well as ACh-induced SK-dependent BP reduction deviations were also evaluated and compared for all groups. Sustained hyperglycemia after the induction of diabetes elevated CRP plasma levels, and reduced ACh-induced SK-dependent BP reduction, observed diabetes-induced variations were minimal in fluoroquinolones treated diabetic groups compared with diabetic control group, In conclusion, the treatment with fluoroquinolone antibiotics in diabetic wistars may be associated with a lowering in CRP levels progression, and improvement in SK vitality, which indicates the importance of treating infections in diabetics by fluoroquinolones to mitigate some vascular complications signs that lead to morbidity and mortality in diabetes.